SCM
Superstring Capital Management Portfolio holdings
AUM
$140M
1-Year Est. Return
323.19%
This Fund
S&P 500
1 Year Est. Return
+323.19%
AUM
$140M
AUM Growth
-$46.8M
(-25%)
Holding
59
Top Buys
| 1 | +$14.4M | |
| 2 | +$6M | |
| 3 | +$5.82M | |
| 4 |
Vertex Pharmaceuticals
VRTX
|
+$5.13M |
| 5 |
Genmab
GMAB
|
+$5.02M |
Top Sells
| 1 | +$18.8M | |
| 2 | +$17.9M | |
| 3 | +$8.08M | |
| 4 |
UroGen Pharma
URGN
|
+$6.64M |
| 5 |
Cogent Biosciences
COGT
|
+$5.21M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Summit Therapeutics
SMMT
$11.6B
| $16.9M | 12.09% |
+892,873
|
|
||
2
Immunovant
IMVT
$6.29B
| $8.88M | 6.35% |
357,606
+68,929
|
|
||
|
3
Cogent Biosciences
COGT
$5.49B
| $8.67M | 6.19% |
225,158
-141,080
|
|
||
4
Savara
SVRA
$1.1B
| $8.66M | 6.19% |
1,585,977
+590,624
|
|
||
|
5
UroGen Pharma
URGN
$1.3B
| $6.96M | 4.98% |
387,371
-330,983
|
|
||
|
DFTX
6
Definium Therapeutics
DFTX
$2.48B
| $6.64M | 4.75% |
351,461
-73,741
|
|
||
7
Vir Biotechnology
VIR
$1.47B
| $6.55M | 4.68% |
+730,548
|
|
||
8
Vaxcyte
PCVX
$6.8B
| $6.42M | 4.59% |
+110,454
|
|
||
9
Celldex Therapeutics
CLDX
$2.3B
| $5.71M | 4.08% |
180,048
+91,740
|
|
||
|
SION
10
Sionna Therapeutics
SION
$1.68B
| $5.65M | 4.04% |
141,024
-39,569
|
|
||
|
11
Genmab
GMAB
$14.6B
| $5.28M | 3.77% |
196,709
+167,547
|
|
||
12
Zai Lab
ZLAB
$1.92B
| $5.19M | 3.71% |
275,818
+78,965
|
|
||
|
13
Vertex Pharmaceuticals
VRTX
$108B
| $4.92M | 3.51% |
+11,010
|
|
||
14
IQVIA
IQV
$29.7B
| $4.38M | 3.13% |
+25,668
|
|
||
|
MPLT
15
MapLight Therapeutics
MPLT
$1.21B
| $3.91M | 2.79% |
+192,139
|
|
||
16
Arvinas
ARVN
$505M
| $3.31M | 2.37% |
+312,620
|
|
||
|
ORKA
17
Oruka Therapeutics
ORKA
$3.42B
| $3.12M | 2.23% |
+63,591
|
|
||
18
United Therapeutics
UTHR
$23.2B
| $3.08M | 2.2% |
5,186
-4,265
|
|
||
19
Travere Therapeutics
TVTX
$4.2B
| $3.05M | 2.18% |
102,754
+64,732
|
|
||
20
Trevi Therapeutics
TRVI
$1.9B
| $3M | 2.14% |
251,566
+103,274
|
|
||
|
ANL
21
Adlai Nortye
ANL
$689M
| $2.87M | 2.05% |
+414,852
|
|
||
22
Cabaletta Bio
CABA
$561M
| $2.87M | 2.05% |
1,066,239
-1,187,311
|
|
||
23
Pfizer
PFE
$145B
| $2.08M | 1.48% |
+74,000
|
|
||
24
Axsome Therapeutics
AXSM
$11.9B
| $1.9M | 1.35% |
11,217
-26,216
|
|
||
25
Oric Pharmaceuticals
ORIC
$767M
| $1.46M | 1.04% |
115,234
-140,136
|
|